A Study to Evaluate the Safety, Tolerability, PK and Efficacy of Hemay5087 in Patients With Advanced Solid Tumors

Sponsor
Ganzhou Hemay Pharmaceutical Co., Ltd
Study ID
NCT07624864
Phase
PHASE1
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Solid Tumors

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Hemay5087 — DRUG
    intravenous infusion，once every 3 weeks

Study Details

An open-label phase I clinical study,which enrolled subjects with advanced solid tumors who have failed to respond to adequate standard therapies or have no available effective standard therapy.

Key Dates

First listed
Jun 3, 2026
Start date
Jul 15, 2026
Status verified
May 2026
Primary completion
Apr 30, 2028
Completion
Jun 30, 2028

Study Design

Enrollment
24 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Experimental group
    Intravenous infusion, Once per treatment cycle

Primary Outcome Measure

Number of participants with adverse events [ Time Frame: 3 weeks of treatment ]

Central Contacts

Related Studies